Reviewing the three drug-drug interactions description in the file `benchmark/dataset/DDInter/DDI.txt` and classified them into different risk levels (Major, Moderate, Minor, and Unknown). 

Generally, Major interactions were highly clinically significant and the drug combinations should be strictly avoided; Moderate interactions may result in exacerbation of the disease of the patient and/or change in therapy; Minor interactions were minimally clinically significant and usually they do not require changes in therapy; Unknown interactions meant that the interaction description was unavailable or incomplete.

Finially, saving the classification list into file /root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/ddinter_annotate_1.json.

Output format  (for reference):
[risk_level_1, risk_level_2, ...]

All intermediate results should be save in `/root/autodl-tmp/biomni_v20260208_tmp/gemini-3-pro-preview/ddinter_annotate_1` directory.

I will start by creating the necessary directories and then reading the content of the `benchmark/dataset/DDInter/DDI.txt` file to understand the drug-drug interaction descriptions.

1. [ ] Create output directories (`/root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview` and `/root/autodl-tmp/biomni_v20260208_tmp/gemini-3-pro-preview/ddinter_annotate_1`).
2. [ ] Read the content of `benchmark/dataset/DDInter/DDI.txt`.
3. [ ] Analyze the descriptions and classify each interaction into Major, Moderate, Minor, or Unknown.
4. [ ] Save the classifications to `/root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/ddinter_annotate_1.json`.

<execute> #!BASH
mkdir -p /root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview
mkdir -p /root/autodl-tmp/biomni_v20260208_tmp/gemini-3-pro-preview/ddinter_annotate_1</execute>
<observation></observation>
I will read the file to see the descriptions of the drug-drug interactions.

<execute> #!BASH
cat benchmark/dataset/DDInter/DDI.txt</execute>
<observation>Drug-Drug Interaction 1:
The concomitant use of fluphenazine and antithyroid agents may theoretically increase the risk of agranulocytosis. The mechanism of this interaction is unknown but may be related to synergistic effects as both drugs have been associated with agranulocytosis.
If these drugs must be used together, close observation and testing for evidence of granulocytopenia is recommended. Patients should be advised to promptly report any symptoms such as tiredness, weakness, sore throat, fever, stomatitis, malaise, or flu-like symptoms.

Drug-Drug Interaction 2:
Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Efavirenz has been associated with hepatotoxicity during postmarketing use.
The risk of hepatic injury should be considered when efavirenz is used in combination with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; other HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of liver function tests should occur before and during treatment, especially in patients with underlying hepatic disease (including hepatitis B or C coinfection) or marked transaminase elevations.

Drug-Drug Interaction 3:
Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of brivaracetam, which is partially metabolized by the isoenzyme. The risk of a clinically relevant CYP450 2C19-mediated interaction is considered to be low according to the manufacturer.
</observation>
I will save the classification results to the specified JSON file.

1. [✓] First step (completed)
2. [✓] Second step (completed)
3. [ ] Third step (Classify and Save)

<execute> import json
import os

# Classification based on analysis
# DDI 1: Moderate (Requires close observation/testing, not strictly avoided)
# DDI 2: Moderate (Requires monitoring, risk consideration, not strictly avoided)
# DDI 3: Minor (Risk considered low)
results = ["Moderate", "Moderate", "Minor"]

output_path = "/root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/ddinter_annotate_1.json"

with open(output_path, 'w') as f:
    json.dump(results, f)

print(f"Results saved to {output_path}")</execute>
<observation>Results saved to /root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/ddinter_annotate_1.json
</observation>
1. [✓] First step (completed)
2. [✓] Second step (completed)
3. [✓] Third step (Classify and Save)

I have completed the task. I will now output the final answer.

The answer is <solution> ["Moderate", "Moderate", "Minor"] </solution>